How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/central-retinal-vein-occlusion-with-macular-edema.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Central retinal vein occlusion with macular edema — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Central retinal vein occlusion with macular edema (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Central retinal vein occlusion with macular edema, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vegf Trap	AFLIBERCEPT	Regeneron	Vascular Endothelial Growth Factor Inhibitor	Vascular endothelial growth factor A	2011-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Eylea	Eylea	Texas Retina Associates		Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B
Lucentis	Lucentis	Santen Inc.		Vascular endothelial growth factor A
BYOOVIZ	RANIBIZUMAB-NUNA	SAMSUNG BIOEPIS CO LTD		Vascular endothelial growth factor A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (originally Merck) · 1 drug in Central retinal vein occlusion with macular edema
Regeneron · 1 drug in Central retinal vein occlusion with macular edema
SAMSUNG BIOEPIS CO LTD · 1 drug in Central retinal vein occlusion with macular edema
Santen Inc. · 1 drug in Central retinal vein occlusion with macular edema
Texas Retina Associates · 1 drug in Central retinal vein occlusion with macular edema

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Central retinal vein occlusion with macular edema:

Cite this brief

Drug Landscape (2026). Central retinal vein occlusion with macular edema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/central-retinal-vein-occlusion-with-macular-edema. Accessed 2026-06-10.

Central retinal vein occlusion with macular edema full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing